William E Whitehead

List of Publications by Year
in descending order

141 papers	21,036 citations	15504 65 h-index	11308 136 g-index
142 all docs	142 docs citations	142 times ranked	9127 citing authors

#	Article	IF	Citations
1	U. S. Householder survey of functional gastrointestinal disorders. Digestive Diseases and Sciences, 1993, 38, 1569-1580.	2.3	1,995
2	Prevalence of Symptomatic Pelvic Floor Disorders in US Women. JAMA - Journal of the American Medical Association, 2008, 300, 1311.	7.4	1,397
3	AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123, 2108-2131.	1.3	1,247
4	Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?. Gastroenterology, 2002, 122, 1140-1156.	1.3	944
5	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 2021, 160, 99-114.e3.	1.3	913
6	Tolerance for Rectosigmoid Distention in Irritable Bowel Syndrome. Gastroenterology, 1990, 98, 1187-1192.	1.3	579
7	Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.gov (trial registry no.) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.3	568
8	Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology, 1997, 112, 2120-2137.	1.3	521
9	Fecal Incontinence in US Adults: Epidemiology and Risk Factors. Gastroenterology, 2009, 137, 512-517.e2.	1.3	521
10	Symptoms of Psychologic Distress Associated With Irritable Bowel Syndrome. Gastroenterology, 1988, 95, 709-714.	1.3	469
11	Irritable bowel syndrome. Digestive Diseases and Sciences, 1980, 25, 404-413.	2.3	455
12	AGA technical review on anorectal testing techniques. Gastroenterology, 1999, 116, 735-760.	1.3	419
13	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	1.3	400
14	Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia. Gastroenterology, 2006, 130, 657-664.	1.3	398
15	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut, 2017, 66, 1075-1082.	12.1	368
16	Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. Digestive Diseases and Sciences, 1997, 42, 223-241.	2.3	347
17	Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. American Journal of Gastroenterology, 2000, 95, 999-1007.	0.4	340
18	Biofeedback Benefits Only Patients With Outlet Dysfunction, Not Patients With Isolated Slow Transit Constipation. Gastroenterology, 2005, 129, 86-97.	1.3	328

#	Article	IF	Citations
19	Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception. Gastroenterology, 1998, 115, 1263-1271.	1.3	288
20	Design of Treatment Trials for Functional Gastrointestinal Disorders. Gastroenterology, 2006, 130, 1538-1551.	1.3	269
21	Randomized, Controlled Trial Shows Biofeedback to be Superior to Alternative Treatments for Patients with Pelvic Floor Dyssynergia-Type Constipation. Diseases of the Colon and Rectum, 2007, 50, 428-441.	1.3	266
22	ACG Clinical Guideline: Management of Benign Anorectal Disorders. American Journal of Gastroenterology, 2014, 109, 1141-1157.	0.4	265
23	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology, 2020, 158, 1262-1273.e3.	1.3	249
24	Epidemiology, Pathophysiology, and Classification of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. American Journal of Gastroenterology, 2015, 110, 127-136.	0.4	219
25	Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial. American Journal of Gastroenterology, 2011, 106, 1678-1688.	0.4	218
26	Treatment options for fecal incontinence. Diseases of the Colon and Rectum, 2001, 44, 131-142.	1.3	207
27	Randomized Controlled Trial Shows Biofeedback to be Superior to Pelvic Floor Exercises for Fecal Incontinence. Diseases of the Colon and Rectum, 2009, 52, 1730-1737.	1.3	206
28	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. The Lancet Gastroenterology and Hepatology, 2018, 3, 252-262.	8.1	199
29	Anorectal functional testing: review of collective experience1. American Journal of Gastroenterology, 2002, 97, 232-240.	0.4	197
30	Design of Treatment Trials for Functional Gastrointestinal Disorders. Gastroenterology, 2016, 150, 1469-1480.e1.	1.3	195
31	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. Neurogastroenterology and Motility, 2020, 32, e13679.	3.0	184
32	Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Current Gastroenterology Reports, 2017, 19, 15.	2.5	181
33	Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Alimentary Pharmacology and Therapeutics, 2007, 26, 237-248.	3.7	177
34	Comorbidity in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2007, 102, 2767-2776.	0.4	176
35	Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Digestive Diseases and Sciences, 2002, 47, 2605-2614.	2.3	172
36	Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome. American Journal of Gastroenterology, 2010, 105, 2228-2234.	0.4	166

#	Article	IF	Citations
37	Functional disorders of the anus and rectum. Gut, 1999, 45, ii55-ii59.	12.1	158
38	Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut, 2007, 56, 1202-1209.	12.1	154
39	Association of Low Dietary Intake of Fiber and Liquids With Constipation: Evidence From the National Health and Nutrition Examination Survey. American Journal of Gastroenterology, 2013, 108, 796-803.	0.4	148
40	Biofeedback treatment of fecal incontinence. Diseases of the Colon and Rectum, 2001, 44, 728-736.	1.3	147
41	Irritable bowel syndrome defined by factor analysis gender and race comparisons. Digestive Diseases and Sciences, 1995, 40, 2647-2655.	2.3	143
42	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. American Journal of Gastroenterology, 2018, 113, 86-96.	0.4	138
43	Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits. American Journal of Gastroenterology, 2008, 103, 2550-2561.	0.4	134
44	Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology, 1990, 98, 336-340.	1.3	132
45	Validation of the Balloon Evacuation Test: Reproducibility and Agreement With Findings From Anorectal Manometry and Electromyography. Clinical Gastroenterology and Hepatology, 2014, 12, 2049-2054.	4.4	131
46	Biofeedback Treatment of Constipation. Diseases of the Colon and Rectum, 2003, 46, 1208-1217.	1.3	130
47	Sensory retraining is key to biofeedback therapy for formed stool fecal incontinence. American Journal of Gastroenterology, 2002, 97, 109-117.	0.4	124
48	Psychological Treatments in Functional Gastrointestinal Disorders: A Primer for the Gastroenterologist. Clinical Gastroenterology and Hepatology, 2013, 11, 208-216.	4.4	118
49	Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complementary and Alternative Medicine, 2008, 8, 46.	3.7	111
50	Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2006, 24, 137-146.	3.7	101
51	Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. American Journal of Obstetrics and Gynecology, 2010, 202, 493.e1-493.e6.	1.3	97
52	Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. Digestive Diseases and Sciences, 1997, 42, 796-804.	2.3	96
53	Mechanisms of Constipation in Older Persons and Effects of Fiber Compared with Placebo. Journal of the American Geriatrics Society, 1995, 43, 666-669.	2.6	91
54	Risk Factors for Urinary, Fecal, or Dual Incontinence in the NursesÊ¼ Health Study. Obstetrics and Gynecology, 2013, 122, 539-545.	2.4	90

#	Article	IF	Citations
55	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. American Journal of Gastroenterology, 2018, 113, 1017-1025.	0.4	90
56	Validation of Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: A Critical Review. American Journal of Gastroenterology, 2010, 105, 814-820.	0.4	89
57	Risk Factors for Fecal Incontinence in Older Women. American Journal of Gastroenterology, 2013, 108, 113-119.	0.4	87
58	Biofeedback Treatment for Functional Anorectal Disorders: A Comprehensive Efficacy Review. Applied Psychophysiology Biofeedback, 2004, 29, 153-174.	1.7	86
59	The usual medical care for irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2004, 20, 1305-1315.	3.7	74
60	Treatment of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases Workshop. American Journal of Gastroenterology, 2015, 110, 138-146.	0.4	74
61	The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. American Journal of Obstetrics and Gynecology, 2007, 197, 636.e1-636.e6.	1.3	73
62	IBS Patients Show Frequent Fluctuations Between Loose/Watery and Hard/Lumpy Stools: Implications for Treatment. American Journal of Gastroenterology, 2012, 107, 286-295.	0.4	72
63	Reports of "Satisfactory Relief" by IBS Patients Receiving Usual Medical Care Are Confounded by Baseline Symptom Severity and Do Not Accurately Reflect Symptom Improvement. American Journal of Gastroenterology, 2006, 101, 1057-1065.	0.4	70
64	Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence. Diseases of the Colon and Rectum, 2015, 58, 983-993.	1.3	67
65	Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report. Gastroenterology, 2009, 137, 1944-1953.e3.	1.3	66
66	ACG Clinical Guidelines: Management of Benign Anorectal Disorders. American Journal of Gastroenterology, 2021, 116, 1987-2008.	0.4	58
67	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). BioPsychoSocial Medicine, 2007, 1, 6.	2.1	57
68	Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar. Journal of Clinical Gastroenterology, 2009, 43, 214-220.	2.2	57
69	Habit Training as Treatment of Encopresis Secondary to Chronic Constipation. Journal of Pediatric Gastroenterology and Nutrition, 1985, 4, 397-401.	1.8	54
70	Management of the multiple symptoms of irritable bowel syndrome. The Lancet Gastroenterology and Hepatology, 2017, 2, 112-122.	8.1	54
71	Hypnosis Home Treatment for Irritable Bowel Syndrome:A Pilot Study. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 85-99.	1.8	53
72	Diagnosis and Treatment of Pelvic Floor Disorders: What's New and What to Do. Gastroenterology, 2010, 138, 1231-1235.e4.	1.3	53

#	Article	IF	Citations
73	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clinical Gastroenterology and Hepatology, 2022, 20, e945-e956.	4.4	52
74	Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. Pain, 2017, 158, 618-628.	4.2	49
75	Diagnosing and Managing Fecal Incontinence: If You Donâ€™t Ask, They Wonâ€™t Tell. Gastroenterology, 2005, 129, 6.	1.3	48
76	The role of biofeedback in the treatment of gastrointestinal disorders. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 371-382.	1.7	48
77	Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 281-283.	3.0	46
78	Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 698-710.	8.1	44
79	Social learning contributions to the etiology and treatment of functional abdominal pain and inflammatory bowel disease in children and adults. World Journal of Gastroenterology, 2007, 13, 2397.	3.3	44
80	Control groups appropriate for behavioral interventions. Gastroenterology, 2004, 126, S159-S163.	1.3	43
81	Hypnosis for Irritable Bowel Syndrome:The Empirical Evidence of Therapeutic Effects. International Journal of Clinical and Experimental Hypnosis, 2006, 54, 7-20.	1.8	43
82	Survey of Geriatricians on the Effect of Fecal Incontinence on Nursing Home Referral. Journal of the American Geriatrics Society, 2010, 58, 1058-1062.	2.6	42
83	Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2011, 23, 944.	3.0	40
84	Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. BMC Complementary and Alternative Medicine, 2009, 9, 24.	3.7	39
85	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. Journal of Neurogastroenterology and Motility, 2015, 21, 537-544.	2.4	39
86	Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. Clinical Gastroenterology and Hepatology, 2020, 18, 385-391.	4.4	37
87	3 Is functional dyspepsia just a subset of the irritable bowel syndrome?. Bailliere's Clinical Gastroenterology, 1998, 12, 443-461.	0.9	35
88	Elevated Vasoactive Intestinal Peptide Concentrations in Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2004, 49, 1236-1243.	2.3	35
89	Episodic Nature of Symptoms in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2014, 109, 1450-1460.	0.4	34
90	Rome III survey of irritable bowel syndrome among ethnic Malays. World Journal of Gastroenterology, 2012, 18, 6475.	3.3	33

#	Article	IF	Citations
91	Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complementary Therapies in Medicine, 2014, 22, 17-20.	2.7	32
92	Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. Gastroenterology, 2018, 155, 661-667.e1.	1.3	30
93	Factor analysis of bowel symptoms in US and Italian populations. Digestive and Liver Disease, 2003, 35, 774-783.	0.9	29
94	Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1450-1456.	2.8	29
95	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome. Clinical Gastroenterology and Hepatology, 2021, 19, 277-287.e3.	4.4	29
96	If We Don't Ask, They Won't Tell: Screening for Urinary and Fecal Incontinence by Primary Care Providers. Journal of the American Board of Family Medicine, 2018, 31, 774-782.	1.5	28
97	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and nonâ€GI symptoms and report differences in healthcare utilization: A populationâ€based study. Neurogastroenterology and Motility, 2019, 31, e13483.	3.0	28
98	Conservative and behavioural management of constipation. Neurogastroenterology and Motility, 2009, 21, 55-61.	3.0	25
99	Factors That Affect Consultation and Screening for Fecal Incontinence. Clinical Gastroenterology and Hepatology, 2015, 13, 709-716.	4.4	25
100	Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. Gastroenterology, 2017, 152, 1915-1921.e1.	1.3	24
101	Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. Gut, 1999, 45, ii78-ii79.	12.1	23
102	Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. American Journal of Medicine, 1999, 107, 33-40.	1.5	23
103	Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. Neurogastroenterology and Motility, 2017, 29, e12919.	3.0	23
104	Relationship between symptoms and quality of life in fecal incontinence. Neurogastroenterology and Motility, 2018, 30, e13241.	3.0	22
105	Validity and reliability of the Malayâ€language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 746-750.	2.8	20
106	Physical Activity, BMI, and Risk of Fecal Incontinence in the Nursesâ€™ Health Study. Clinical and Translational Gastroenterology, 2018, 9, e200.	2.5	20
107	Priorities for treatment research from different professional perspectives. Gastroenterology, 2004, 126, S180-S185.	1.3	19
108	Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. North Carolina Medical Journal, 2016, 77, 211-215.	0.2	19

#	Article	IF	Citations
109	Improving biofeedback for the treatment of fecal incontinence in women: implementation of a standardized multiâ€site manometric biofeedback protocol. Neurogastroenterology and Motility, 2017, 29, e12906.	3.0	19
110	Functional gastrointestinal disorders are increased in joint hypermobilityâ€related disorders with concomitant postural orthostatic tachycardia syndrome. Neurogastroenterology and Motility, 2020, 32, e13975.	3.0	19
111	Phenotypic profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of chronic pain patients. Pain, 2021, 162, 1528-1538.	4.2	19
112	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterology Journal, 2021, 9, 1178-1188.	3.8	18
113	Controlling anal incontinence in women by performing anal exercises with biofeedback or loperamide (CAPABLe) trial: Design and methods. Contemporary Clinical Trials, 2015, 44, 164-174.	1.8	17
114	Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterology and Motility, 2016, 28, 783-792.	3.0	17
115	A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia. Pain, 2020, 161, 2860-2871.	4.2	17
116	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterology and Motility, 2021, 33, e14070.	3.0	17
117	Development and validation of new disease-specific measures of somatization and comorbidity in IBS. Journal of Psychosomatic Research, 2012, 73, 351-355.	2.6	16
118	Factors associated with fecal incontinence in a nationally representative sample of diabetic women. International Urogynecology Journal, 2015, 26, 1483-1488.	1.4	16
119	Randomised clinical trial: exploratory phase 2 study of <scp>ONO</scp>â€2952 in diarrhoeaâ€predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 14-26.	3.7	16
120	Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterology and Motility, 2018, 30, e13378.	3.0	16
121	Hypnosis for non-cardiac chest pain. Gut, 2006, 55, 1381-1384.	12.1	15
122	A multicenter study of anorectal pressures and rectal sensation measured with portable manometry in healthy women and men. Neurogastroenterology and Motility, 2021, 33, e14067.	3.0	14
123	Patient preferences for endpoints in fecal incontinence treatment studies. Neurogastroenterology and Motility, 2017, 29, e13032.	3.0	11
124	Disorders of gutâ€brain interaction: Highly prevalent and burdensome yet underâ€taught within medical education. United European Gastroenterology Journal, 2022, 10, 736-744.	3.8	10
125	Obstetric Sphincter Injury Interacts With Diarrhea and Urgency to Increase the Risk of Fecal Incontinence in Women With Irritable Bowel Syndrome. Female Pelvic Medicine and Reconstructive Surgery, 2013, 19, 40-45.	1.1	9
126	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1315-1325.e4.	4.4	9

#	Article	IF	Citations
127	Likelihood of Nursing Home Referral for Fecally Incontinent Elderly Patients is Influenced by Physician Views on Nursing Home Care and Outpatient Management of Fecal Incontinence. Journal of the American Medical Directors Association, 2012, 13, 350-354.	2.5	8
128	Impact of Eating Restriction on Gastrointestinal Motility in Adolescents With IBS. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 491-494.	1.8	7
129	Is Fecal Incontinence a Risk Factor for Institutionalization in the Elderly?. American Journal of Gastroenterology, 2011, 106, 366-367.	0.4	6
130	Biofeedback for fecal incontinence and constipation: The role of medical management and education. Gastroenterology, 2001, 120, A397.	1.3	5
131	Hypnosis and upper digestive function and disease. World Journal of Gastroenterology, 2008, 14, 6276.	3.3	5
132	Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods. Contemporary Clinical Trials, 2021, 107, 106464.	1.8	4
133	Adopting new enrollment criteria for pharmaceutical trials in constipation: look before leaping. Therapeutic Advances in Gastroenterology, 2011, 4, 165-168.	3.2	2
134	Validity and Reliability of the Malay Versions of Bloating Severity (BSQ-M) and Quality of Life (BLQoL-M) Questionnaires. International Journal of Environmental Research and Public Health, 2021, 18, 2487.	2.6	2
135	Proinflammatory Diet Is Associated With Increased Risk of Fecal Incontinence Among Older Women: Prospective Results From the Nursesâ€™ Health Study. Clinical Gastroenterology and Hepatology, 2023, 21, 1657-1659.e3.	4.4	2
136	Anorectal physiology in health: A randomized trial to determine the optimum catheter for the balloon expulsion test. Neurogastroenterology and Motility, 2019, 31, e13582.	3.0	1
137	Constipation. Obstetrics and Gynecology, 2007, 109, 985-989.	2.4	0
138	Is biofeedback therapy an effective treatment for dyssynergic defecation?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 74-75.	1.7	0
139	Editorial: <scp>ONO</scp>â€2952 in irritable bowel syndrome with diarrhoea â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1005-1005.	3.7	0
140	The Prevalence and Risk of Fecal Incontinence in Patients with Cystic Fibrosis: Nothing to Sneeze At. Digestive Diseases and Sciences, 2018, 63, 818-819.	2.3	0
141	Fecal Incontinence. , 2020, , 427-430.		0